Hengrui Yuanzheng focuses on developing immunocellular therapies for solid tumors, with multiple product pipelines including MASCT, TCR-T, and TCR bispecific candidates. Its MASCT program is described as the world’s first clinically approved multi‑target cell therapy for solid tumors and has entered Phase II clinical trials. The company is actively advancing those clinical programs while maintaining a pipeline of next‑generation TCR‑based approaches. Recent financing activity shows continuing investor support. Hengrui Yuanzheng completed a C+ round of financing totaling nearly ¥100 million. The reported investors include Zijin Port Capital, which continued to follow on, alongside Zhongke Kechuang and other institutional backers. Hengrui Yuanzheng focuses on immunocyte therapies for solid tumors, developing multiple product lines including MASCT, TCR-T and TCR bispecifics. Its MASCT program is the world’s first clinically approved multi-target cell therapy for solid tumors and has entered Phase II. The company’s ReGET platform (Reverse Genetic Engineering of TCR-T) enables rapid isolation of high-affinity TCRs from patients and has generated extensive TCR data based on Asian HLA types. Hengrui Yuanzheng’s lead TCR-T candidate, HRYZ-T101, received an IND from the CDE and has China and US patents plus broad PCT coverage. The firm built a Shanghai Songjiang headquarters and a Yangtze River Delta regional cell preparation center in 2021. Financially, it has completed multiple financings and recently closed a C round of over RMB 200 million.

Total raised

$43M

Funding rounds

2

Latest round

Series C

Latest activity

Jan 2024